Who qualifies for a GLP-1 in 2026: BMI, PA, and the Foundayo shift

The gate, in two numbers

If you're in the US and trying to figure out whether a GLP-1 is even on the table for you, here's the FDA label, no fluff: BMI 30 or higher — or BMI 27 or higher with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or established cardiovascular disease). That is the eligibility floor for both Wegovy (semaglutide, FDA approval June 2021) and Zepbound (tirzepatide, FDA approval November 2023). Same gate. Different molecule.

That's the FDA. Your insurer's gate is a different fight, and we'll get to that.

A quick reality check before you scroll: the gate moves when you cross a border. Japan's PMDA approved Wegovy in March 2023 with a much stricter cutoff — BMI 35, or BMI 27 with at least two complications. China uses BMI 28, not 27, as the comorbidity threshold. Korea's label uses 30/27 like ours, but Korean clinical practice often treats BMI 25 as the start of obesity. So if a friend in Tokyo or Seoul tells you their endocrinologist said no, they're not gatekeeping — they're working a different rulebook.

One more 2026-specific thing to know before we go deeper. On April 1, 2026, the FDA approved Foundayo (orforglipron), the first oral GLP-1 with no fasting requirement, at a $149/month list price. That changes who starts on something this year, and we'll cover what it means for your decision below.

What "qualifies" actually means in the US

There are three gates, and people conflate them constantly.

The FDA label is the legal indication — what the prescribing information says. For Wegovy and Zepbound, it's the BMI 30 / BMI 27-with-comorbidity rule.

The prescriber's clinical judgment is whether your doctor thinks GLP-1 therapy is appropriate for you. They can decline even if you meet the label. They can also try to get you on it under a comorbidity you didn't realize you had — borderline hypertension at 138/88, prediabetic A1C of 5.9, untreated mild OSA you've been complaining about for years.

The payer's coverage policy is the real boss fight. Your commercial plan might require BMI 30, six months of documented diet-and-exercise failure, a prior trial of metformin or phentermine, and a re-authorization every 6 months. UnitedHealthcare, Aetna, and Cigna each write their own criteria. Two people with identical clinical pictures can get a yes from one PBM and a no from another because of plan-level policy, not medicine.

The label says you're eligible. The PA says you're approved. Those are not the same sentence, and most denials happen between them.

So when you walk into your appointment, the question you're answering isn't "do I qualify?" It's three questions stacked: do I meet the FDA criteria, will my doctor prescribe, and will my plan pay.

Where Americans actually get a prescription

You have more on-ramps than you did even two years ago. Each one prices and gates the experience differently.

Primary care. Your PCP can prescribe Wegovy or Zepbound in 49 states without a specialty referral. This is the cheapest path if you have insurance — your usual copay applies. PCPs vary wildly in comfort with GLP-1 management; if yours is hesitant, ask for a referral instead of arguing.

Endocrinology or obesity medicine. Board-certified obesity medicine specialists (look for ABOM certification) tend to be faster on titration adjustments and better at writing PA appeals. Wait times in 2026 are 6 to 14 weeks in major metros. Worth the wait if your case is complicated — class III obesity, post-bariatric regain, multiple failed prior medications.

Telehealth weight-loss clinics. Ro, Hims, Henry Meds, Noom Med, and Weight Watchers Clinic all do GLP-1 prescriptions over video. Pricing is typically $99–$199/month for the visit, plus the medication. Most accept commercial insurance for the drug; some don't. The Ro Body program prescribes branded Wegovy or Zepbound and bills your insurance for the medication. Henry Meds historically leaned into compounded semaglutide; post-2024 FDA enforcement they've shifted away from that for most patients.

Manufacturer DTC pharmacies. LillyDirect (Eli Lilly's direct-to-consumer pharmacy) sells Zepbound single-vial doses for $349/month at the lowest dose, scaling to $499/month at higher doses, cash, no insurance involvement. NovoCare offers a Wegovy savings card that drops your copay to as low as $0 if you have commercial insurance and your plan covers it, or $499/month if you're paying cash.

If your PA gets denied and you don't want to fight it, LillyDirect is the path most people end up on. $349 is not nothing, but it's not $1,349 either.

The four-path price snapshot: list price ~$1,349/month, with-insurance copay $0–$200/month after coupon, LillyDirect cash $349–$499/month, NovoCare cash $499/month.

The Medicare moment in July 2026

This is the policy change reshaping access for people 65+. Effective July 1, 2026, Medicare Part D begins covering Wegovy for adults with established cardiovascular disease and a BMI of 27 or higher under the CV-risk-reduction indication that the FDA added in March 2024. CMS estimated typical out-of-pocket cost at roughly $50/month copay through Part D, depending on plan tier.

The fine print matters. This is not Medicare covering Wegovy for obesity in general — that's still blocked by the 2003 Medicare Modernization Act language excluding "weight loss" drugs. The path is the CV indication: you need documented cardiovascular disease (prior heart attack, stroke, peripheral artery disease, or established coronary disease), and a BMI of at least 27. If you have type 2 diabetes plus CV disease, you've had options through Ozempic for years. The new piece is the obesity-CV pathway opening up.

Medicaid is a separate story and varies state by state. As of April 2026, fewer than half of state Medicaid programs cover Wegovy or Zepbound for obesity without a separate qualifying condition. North Carolina, Pennsylvania, and California have broader coverage; Texas and Florida remain restrictive.

Foundayo (orforglipron): what changes when the pill arrives

The April 1, 2026 FDA approval of Foundayo is the first oral GLP-1 with no fasting or water-volume requirement (Rybelsus, the only other oral GLP-1, requires fasting and a specific water protocol that 30+ minutes before food). Foundayo's list price is $149/month — that's roughly one-ninth the list price of Wegovy and the cheapest branded GLP-1 by a significant margin.

Who is this for? Practically: people who hate needles, people whose insurance won't cover an injectable, and people whose work schedule makes weekly subcutaneous shots a logistical headache. It's also a real on-ramp for clinicians who've been hesitant to start patients on Wegovy or Zepbound because of cost — at $149 cash, the math changes.

Caveats. The phase 3 trial program (ATTAIN-1, ATTAIN-2) reported roughly 11–12% mean body weight reduction at 72 weeks for the highest dose. That's lower than tirzepatide's 22.5% at the high dose in SURMOUNT-1, and a step below semaglutide's 15.2% in STEP 1. Foundayo is real, but it's not Zepbound's equal on weight outcomes. For some patients that tradeoff is fine. For others — class III obesity, severe metabolic dysfunction — it's probably not the right starting point.

The eligibility gate for Foundayo is the same as Wegovy and Zepbound: BMI 30, or BMI 27 with a weight-related comorbidity.

The brand-by-market matrix

This is the table that trips people up the most. Same molecule, different brand, different indication depending on which country's regulator you're working with.

Saudi Arabia (SFDA) and the UAE (MOHAP/DHA) generally mirror the FDA-aligned label set: Wegovy, Mounjaro, Saxenda, and Rybelsus are registered for prescription use, with private-pay being the dominant access path.

A few traps from this table that even experienced patients miss:

Mounjaro is not Zepbound. Mounjaro is the type 2 diabetes brand of tirzepatide in the US. Zepbound is the obesity brand. Same molecule, different label, different insurance coverage rules. A US patient asking for "Mounjaro for weight loss" is asking for something off-label. Outside the US — Korea, EU, Japan — there is no Zepbound brand at all, and the obesity-approved tirzepatide is sold under the Mounjaro name.

Japan is the strictest market for tirzepatide. Mounjaro in Japan is approved only for type 2 diabetes as of April 2026. Tirzepatide for obesity is not approved there at all. If a Japanese patient wants tirzepatide for weight loss specifically, the on-label option is ウゴービ (Wegovy) — period.

France's Ozempic stockout was an off-label problem. During 2023 and 2024, France saw a national Ozempic shortage driven by off-label obesity prescribing, even though Wegovy was the on-label semaglutide-for-obesity option. That story matters because it's the cleanest example of the brand-vs-indication confusion creating a real-world supply crisis.

The BMI threshold matrix

Same gate for most of the world. Three exceptions worth knowing.

Japan deserves a callout. A BMI of 35 puts you in what US clinicians call class II obesity. That is the floor for an on-label Wegovy prescription in Japan under the strict interpretation of the PMDA criteria, and it's coupled with the requirement that a qualifying institution prescribes it. The PMDA criteria also recognize a 27-with-two-complications path, but in practice many Japanese clinicians stick to the 35 cutoff to stay clean for public insurance reimbursement. The result: a Japanese patient with a BMI of 32 and one comorbidity who would qualify in the US, EU, Korea, or the Gulf states does not qualify on label in Japan. Their options are 自由診療 (self-pay private practice) or wait.

The eligibility-counted comorbidities are mostly consistent across markets: type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, established cardiovascular disease, and in some labels NAFLD or MASH. Adolescent eligibility (12–17 years) for Wegovy is on label in the US and EU at BMI ≥ 95th percentile; Korea, Japan, and China remain adult-only as of April 2026.

Questions to bring to your doctor

These are the high-leverage questions for a US patient walking into a 20-minute visit. Don't try to ask all of them — pick three or four that map to your situation.

1. What's my plan's PA history with GLP-1s, and have you written one before for this insurer? Some practices keep notes on which payer requires what. Asking this signals you're serious and saves a denial cycle.
2. If we're working a comorbidity path, which one are we documenting? If you're in the BMI 27–30 zone, the comorbidity choice changes the PA narrative. Hypertension and dyslipidemia are the cleanest. OSA is strong if you have a sleep study. Prediabetes (A1C 5.7–6.4) often qualifies but varies by plan.
3. Should I get an OSA work-up before we file? A documented sleep study showing AHI ≥ 5 is one of the cleanest comorbidity boxes to check, and untreated mild OSA is genuinely common in the BMI 27–32 range.
4. What's my baseline alcohol use, and does that change anything for you? GLP-1s have an emerging interaction profile with alcohol — reduced cravings for some, increased nausea sensitivity for others. Worth being honest about, even if it's awkward.
5. Should we screen for type 2 diabetes before starting? A fasting glucose and A1C cost nothing to add to a visit, and an A1C of 6.5 or higher reroutes the entire treatment algorithm.
6. If the PA gets denied, what's our appeal plan? A practice that has a documented appeal template will get you through faster than one improvising. Ask.
7. Are you comfortable managing GI side effects, or do I follow up with someone else? Nausea, constipation, and reflux at week 4–8 are the period most patients quit. Knowing your titration support up front matters.

What to verify before you fill the prescription

Before the e-prescribe lands at your pharmacy, run this checklist. It saves money and surprise.

• Plan formulary status. Call the number on the back of your card and ask: "Is Wegovy [or Zepbound, or Foundayo] on formulary, and what tier?" Tier 2 is typical; Tier 3 with PA is common; non-formulary means a fight.
• Manufacturer copay savings. NovoCare (Wegovy) and the LillyDirect savings card (Zepbound) can drop your copay to as low as $0/month with commercial insurance. Government insurance (Medicare, Medicaid, TRICARE, VA) is excluded from these programs by federal rules.
• Mail-order vs. retail. Most PBMs (CVS Caremark, Express Scripts, OptumRx) push specialty drugs to mail-order after the first fill. Mail-order is cheaper per fill but breaks your titration if shipping delays hit. Plan for it.
• Cold-chain handling. Wegovy and Zepbound need refrigeration (36–46°F / 2–8°C). If your mail-order ships in summer heat without a gel pack, the dose may be compromised. Some patients ask for retail pickup specifically for the May–September window.
• Titration schedule and pen count. Wegovy goes 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks. Zepbound goes 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg over 20 weeks. Each dose change requires a new prescription strength, and your pharmacy may need 48–72 hours to swap. Don't run out before you titrate.
• Expiration after first use. Once a Wegovy pen is in use, it's stable for 28 days at room temperature or in the fridge. Mark the date on the pen with a Sharpie — you will forget.
• Storage if you travel. TSA allows GLP-1 pens in carry-on with prescription labeling. International travel requires a doctor's letter for some destinations (UAE, Singapore, Saudi Arabia have stricter import documentation rules).

The single most common reason a first fill goes sideways isn't the medication — it's a mismatch between what the plan covers and what the doctor wrote. Calling your PBM the day the prescription is sent is worth the 12 minutes it takes.

The compounded-tirzepatide question, briefly

Through the 2024 FDA-declared shortage period, 503A and 503B compounding pharmacies were producing semaglutide and tirzepatide at roughly $200–$400/month — and a lot of telehealth weight-loss clinics built businesses on that supply. The shortage was officially resolved in October 2024, and FDA enforcement against bulk compounded GLP-1s has tightened through 2025 and into 2026.

Where this lands as of April 2026: 503B outsourcing facilities have largely exited bulk compounded semaglutide and tirzepatide. 503A pharmacies still compound for individual patient-specific prescriptions, but the legal ground is narrower. Some patients are still on compounded; many have transitioned to LillyDirect or NovoCare cash programs since list-equivalent branded options are now accessible at cash prices much closer to compounded rates.

If you're currently on compounded tirzepatide, the conversation with your prescriber is whether to transition to Zepbound. If you're considering starting on compounded, the math has shifted — $349/month LillyDirect Zepbound is in the same neighborhood as a lot of compounded programs, and you get an FDA-approved product, a real titration schedule, and pharmacy-grade cold chain.

How a non-US reader should read this article

If you're reading this from Seoul, Tokyo, Madrid, Riyadh, Dubai, Hong Kong, Taipei, or Shanghai — the BMI numbers above are the global label-level summary, but your real on-the-ground experience differs in two ways. Coverage is mostly self-pay outside the US (Korean NHIS doesn't reimburse obesity GLP-1s, France's Sécurité Sociale doesn't reimburse Wegovy for obesity, Korea's NHIS treats all obesity GLP-1s as 비급여, Japan reimburses ウゴービ only when the strict criteria are met at a qualifying institution). And brand availability differs — Zepbound does not exist outside the US as a brand, and Foundayo as of April 2026 is US-only.

The Blueshot blog has localized versions of this piece written by editors in those markets, with the local clinic, payer, and pharmacy specifics for each one. If you want the version with Korean NHIS rules and 비만클리닉 prescriber norms, or the Japan version with the strict PMDA criteria explained from the patient side, those exist. The numbers in this US-first piece are accurate as a global reference; the lived experience is what your local Blueshot localization covers.

What to actually do this week

If you've read this far, you probably fall into one of three buckets.

Bucket 1: you meet the BMI 30 floor and have commercial insurance. Book a PCP visit for the next two weeks. Bring your last labs (or get them drawn before the visit). Ask question 1, 2, and 6 from the list above. If the PA is denied, file an appeal — first-pass denial rates run 30–50% across major payers, but appeal success rates are 60%+ when the documentation is clean.

Bucket 2: you're at BMI 27–30 with a possible comorbidity. Get the comorbidity work-up done before the GLP-1 conversation. A sleep study, a lipid panel, a fasting glucose and A1C, a couple of blood pressure readings logged over two weeks. Walk into the appointment with the documentation already in hand. This is the difference between a 4-week PA cycle and a 12-week one.

Bucket 3: you don't have insurance coverage that will work, or you're on Medicare without CV disease. Look at LillyDirect Zepbound at $349/month, NovoCare Wegovy at $499/month cash, or Foundayo at $149/month if your prescriber thinks the lower expected weight loss is acceptable for your case. Pick the option you can sustain for at least 12 months — GLP-1s only work as long as you take them, and SURMOUNT-4 and STEP 4 both showed regain when patients stopped.

The drug is the easy part. Getting through the gate is the work. Bring this list to your next visit and you'll be in front of most people walking in cold.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app